Vertex Pharmaceuticals (VRTX) is a publicly traded Healthcare sector company. As of July 5, 2026, VRTX trades at $528.04 with a market cap of $134.02B and a P/E ratio of 31.04. VRTX moved +6.03% today. Year to date, VRTX is +16.38%; over the trailing twelve months it is +15.54%. Its 52-week range spans $362.50 to $529.14. Analyst consensus is strong buy with an average price target of $562.95. Rallies surfaces VRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for VRTX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $528.04 |
| Market Cap | $134.02B |
| P/E Ratio | 31.04 |
| EPS | $17.01 |
| Dividend Yield | 0.00% |
| 52-Week High | $529.14 |
| 52-Week Low | $362.50 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $12.22B |
| Net Income | $4.34B |
| Gross Margin | 86.24% |
24 analysts cover VRTX: 0 strong buy, 19 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $562.95.